Scholarlink

Background <p>Ritlecitinib, an oral selective inhibitor of Janus kinase 3 and the TEC family of kinases, has recently been approved for the treatment of severe alopecia areata, but real-world data are still limited.</p> Objective <p>The aim was to evaluate the effectiveness and tolerability of ritlecitinib 50 mg/day after 24 weeks in patients with severe alopecia areata in clinical practice.</p> Methods <p>We performed an Italian observational, retrospective, multicentre study with 24 weeks of follow-up. Patients ≥ 12 years of age with severe alopecia areata (Severity of Alopecia Tool [SALT] ≥&#xa0;50) and a disease duration ≥&#xa0;6 months who were candidates for systemic therapy were enrolled. Ritlecitinib 50 mg/day was administered according to national guidelines. The primary endpoint was to evaluate the achievement of SALT ≤ 20 at week 24. Secondary endpoints included achievement of SALT ≤ 10; mean change in SALT; trichoscopic improvement; quality of life; psychological impact; efficacy in eyebrows, eyelashes, and nails; and safety profile.</p> Results <p>A total of 102 patients were included. At week 24, 40.2% of patients achieved SALT ≤ 20, with a greater response in adolescents (48.6%) than in adults (21.9%). The mean SALT score decreased from 86.2 ± 18.5 to 40.8 ± 37.1. Significant improvements were observed in trichoscopic signs and quality of life. The treatment was also effective on eyebrows, eyelashes, and nails. Adverse events were mild (e.g., acne, headache). Ritlecitinib had to be discontinued in only one case of severe anaemia.</p> Conclusions <p>In this multicentre real-world study, ritlecitinib 50 mg/day was an effective and well-tolerated treatment option for severe alopecia areata.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Michela Starace,
  • Luca Rapparini,
  • Francesca Pampaloni,
  • Stephano Cedirian,
  • Federico Quadrelli,
  • Francesca Bruni,
  • Ginevra Martelli,
  • Giampiero Girolomoni,
  • Francesco Bellinato,
  • Paolo Gisondi,
  • Giuseppe Gallo,
  • Simone Ribero,
  • Michela Ortoncelli,
  • Pietro Quaglino,
  • Luigi Gargiulo,
  • Carlo Vignoli,
  • Alessandra Narcisi,
  • Francesca Ambrogio,
  • Caterina Foti,
  • Raffaele Dante Caposiena Caro,
  • Iris Zalaudek,
  • Angelo Valerio Marzano,
  • Andrea Sechi,
  • Mauro Barbareschi,
  • Luca Valtellini,
  • Silvia Mariel Ferrucci,
  • Laura Diluvio,
  • Enrico Matteini,
  • Luca Bianchi,
  • Mariateresa Cantelli,
  • Paola Nappa,
  • Carolina D’Elia,
  • Valeria Boccaletti,
  • Carola Romanò,
  • Elisabetta Fulgione,
  • Anna Balato,
  • Giuseppe Argenziano,
  • Emanuele Trovato,
  • Elisa Cinotti,
  • Pietro Rubegni,
  • Federica Dall’Oglio,
  • Francesco Lacarrubba,
  • Giuseppe Micali,
  • Elena Pezzolo,
  • Francesca Caroppo,
  • Anna Belloni Fortina,
  • Giacomo Caldarola,
  • Ketty Peris,
  • Lorenzo Maria Pinto,
  • Calogero Pagliarello,
  • Riccardo Balestri,
  • Carlo Tomasini,
  • Stefania Barruscotti,
  • Laura Atzori,
  • Silvia Sanna,
  • Lorenzo Ala,
  • Giulio Bortone,
  • Giovanni Pellacani,
  • Alfredo Rossi,
  • Serena Lembo,
  • Annunziata Raimondo,
  • Flavia Manzo Margiotta,
  • Valentina Dini,
  • Marco Romanelli,
  • Andrea Megna,
  • Francesca Prignano,
  • Gianmarco Silvi,
  • Oriana Simonetti,
  • Edoardo De Simoni,
  • Michela Magnano,
  • Natale Schettini,
  • ⁠⁠Alessandro Borghi,
  • Francesca Satolli,
  • Maria Beatrice de Felici del Giudice,
  • Franco Rongioletti,
  • Stefania Guida,
  • Gianmarco Diego Bigotto,
  • Cesare Filippeschi,
  • Teresa Oranges,
  • Greta Tronconi,
  • Bianca Maria Piraccini

摘要

Background

Ritlecitinib, an oral selective inhibitor of Janus kinase 3 and the TEC family of kinases, has recently been approved for the treatment of severe alopecia areata, but real-world data are still limited.

Objective

The aim was to evaluate the effectiveness and tolerability of ritlecitinib 50 mg/day after 24 weeks in patients with severe alopecia areata in clinical practice.

Methods

We performed an Italian observational, retrospective, multicentre study with 24 weeks of follow-up. Patients ≥ 12 years of age with severe alopecia areata (Severity of Alopecia Tool [SALT] ≥ 50) and a disease duration ≥ 6 months who were candidates for systemic therapy were enrolled. Ritlecitinib 50 mg/day was administered according to national guidelines. The primary endpoint was to evaluate the achievement of SALT ≤ 20 at week 24. Secondary endpoints included achievement of SALT ≤ 10; mean change in SALT; trichoscopic improvement; quality of life; psychological impact; efficacy in eyebrows, eyelashes, and nails; and safety profile.

Results

A total of 102 patients were included. At week 24, 40.2% of patients achieved SALT ≤ 20, with a greater response in adolescents (48.6%) than in adults (21.9%). The mean SALT score decreased from 86.2 ± 18.5 to 40.8 ± 37.1. Significant improvements were observed in trichoscopic signs and quality of life. The treatment was also effective on eyebrows, eyelashes, and nails. Adverse events were mild (e.g., acne, headache). Ritlecitinib had to be discontinued in only one case of severe anaemia.

Conclusions

In this multicentre real-world study, ritlecitinib 50 mg/day was an effective and well-tolerated treatment option for severe alopecia areata.